Canlyniadau Chwilio - Noriko Yanagitani

Mireinio'r Canlyniadau
  1. 1
    Association of the <i>OGG1</i>‐Ser326Cys polymorphism with lung adenocarcinoma risk

    Association of the <i>OGG1</i>‐Ser326Cys polymorphism with lung adenocarcinoma risk gan Takashi Kohno, Hideo Kunitoh, Kaoru Toyama, Seiichiro Yamamoto, Aya Kuchiba, Daizo Saito, Noriko Yanagitani, Shinichi Ishihara, Ryusei Saito, Jun Yokota

    Cyhoeddwyd 2006
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy

    Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy gan Ryo Ariyasu, Atsushi Horiike, Takahiro Yoshizawa, Yosuke Dotsu, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens

    Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regi... gan Mayu Sugai, Yoshiaki Amino, Seitaro Fujishima, Kyujiro Nibuya, Hirokazu Iso, Masahiro Ito, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Noriko Yanagitani, Makoto Nishio

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Prognostic significance of L‐type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung

    Prognostic significance of L‐type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung gan Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Masatomo Mori

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer

    Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer gan Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Shigebumi Tanaka, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takahiro Nakajima, Masatomo Mori

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    <scp>l</scp>‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms

    <scp>l</scp>‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms gan Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, Kimihiro Shimizu, Noriko Yanagitani, Noriaki Sunaga, Takeshi Hisada, Shigebumi Tanaka, Tamotsu Ishizuka, Yoshikatsu Kanai, Hitoshi Endou, Takashi Nakajima, Masatomo Mori

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Detection of epidermal growth factor receptor T790M mutation in plasma <scp>DNA</scp> from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

    Detection of epidermal growth factor receptor T790M mutation in plasma <scp>DNA</scp> from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor gan Kazuko Sakai, Atsushi Horiike, Darryl Irwin, Keita Kudo, Yoshihiko Fujita, Azusa Tanimoto, Toshio Sakatani, Ryota Saito, Kyohei Kaburaki, Noriko Yanagitani, Fumiyoshi Ohyanagi, Makoto Nishio, Kazuto Nishio

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

    Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms gan Noriko Yanagitani, Ken Uchibori, Sumie Koike, Mika Tsukahara, Satoru Kitazono, Takahiro Yoshizawa, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Tambo, Shingo Nishikawa, Naoya Fujita, Ryohei Katayama, Makoto Nishio

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

    Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer gan Bo Gong, Kazuma Kiyotani, Seiji Sakata, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio, Kengo Takeuchi, Hiroshi Kawamoto, Naoya Fujita, Ryohei Katayama

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors

    Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand... gan Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Shinya Uematsu, Takahiro Yoshizawa, Tsukasa Hasegawa, Ken Uchibori, Noriko Yanagitani, Atsushi Horiike, Takeshi Horai, Masahiro Seike, Akihiko Gemma, Makoto Nishio

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

    Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results fro... gan David Planchard, Po‐Hao Feng, Nina Karaseva, S.-W. Kim, T.M. Kim, Chee Khoon Lee, Artem Poltoratskiy, Noriko Yanagitani, Ryan Marshall, X. Huang, Paul Howarth, Pasi A. Jänne, Kunihiko Kobayashi

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

    Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy gan Noriaki Sunaga, David S. Shames, Luc Girard, Michael Peyton, Jill E. Larsen, Hisao Imai, Junichi Soh, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira, Yang Xie, Adi F. Gazdar, Masatomo Mori, John D. Minna

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Association of amino acid substitution polymorphisms in DNA repair genes <i>TP53</i>, <i>POLI</i>, <i>REV1</i> and <i>LIG4</i> with lung cancer risk

    Association of amino acid substitution polymorphisms in DNA repair genes <i>TP53</i>, <i>POLI</i>, <i>REV1</i> and <i>LIG4</i> with lung cancer risk gan Tokuki Sakiyama, Takashi Kohno, Sachiyo Mimaki, Tsutomu Ohta, Noriko Yanagitani, Tomotaka Sobue, Hideo Kunitoh, Ryusei Saito, Kimiko Shimizu, Chie Hirama, Junko Kimura, Go Maeno, Hiroshi Hirose, Takashi Eguchi, Daizo Saito, Misao Ohki, Jun Yokota

    Cyhoeddwyd 2004
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

    Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations gan Satoshi Morita, Isamu Okamoto, Kunihiko Kobayashi, Koichi Yamazaki, Hajime Asahina, Akira Inoue, Koichi Hagiwara, Noriaki Sunaga, Noriko Yanagitani, Toyoaki Hida, Kimihide Yoshida, Tomonori Hirashima, Kosei Yasumoto, Kenji Sugio, Tetsuya Mitsudomi, Masahiro Fukuoka, Toshihiro Nukiwa

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

    Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance gan Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh‐hara, Kana Watanabe, Keiichi Tamai, Makoto Maemondo, Makoto Nishio, Takeshi Ishikawa, Yasushi Okuno, Naoya Fujita, Ryohei Katayama

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation

    Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation gan Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun, Ken Uchibori, Makoto Nishio, Yasunari Miyazaki, Yuichi Shiraishi, Seishi Ogawa, Keisuke Kataoka, Naoya Fujita, Kengo Takeuchi, Ryohei Katayama

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status

    Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status gan Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nishiyama, Takayuki Nakagawa, Hirokazu Taniguchi, Takeshi Suzuki, Tadaaki Yamada, Hiroshi Nishihara, Hironori Ninomiya, Yuichi Ishikawa, Satoko Baba, Kengo Takeuchi, Atsushi Horiike, Noriko Yanagitani, Makoto Nishio, Seiji Yano

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

    P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer gan Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani, Hironori Ninomiya, Atsushi Horiike, Luc Friboulet, Justin F. Gainor, Noriko Motoi, Akito Dobashi, Seiji Sakata, Yuichi Tambo, Satoru Kitazono, Shigeo Sato, Sumie Koike, A. John Iafrate, Mari Mino‐Kenudson, Yuichi Ishikawa, Alice T. Shaw, Jeffrey A. Engelman, Kengo Takeuchi, Makoto Nishio, Naoya Fujita

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

    The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models gan Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh‐hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

    Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer gan Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh‐hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto‐Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: